Belite Bio, Inc. 今日正式对外发布公告，称美国食品药品监督管理局（FDA）已正式受理其针对1型Stargardt病（一种遗传性视网膜病变）的治疗药物Tinlarebant所提交的新药申请（NDA）。更令人瞩目的是，该申请同时被授予了优先审评资格。这一决定标志着该药物在通往获批上市的道路上迈出了至关重要的一步，为饱受此类罕见眼疾困扰的患者群体带来了新的希望。
Belite Bio, Inc. 今日正式对外发布公告，称美国食品药品监督管理局（FDA）已正式受理其针对1型Stargardt病（一种遗传性视网膜病变）的治疗药物Tinlarebant所提交的新药申请（NDA）。更令人瞩目的是，该申请同时被授予了优先审评资格。这一决定标志着该药物在通往获批上市的道路上迈出了至关重要的一步，为饱受此类罕见眼疾困扰的患者群体带来了新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.